Libtayo, the skin cancer drug made by Sanofi and Regeneron, has been approved by the U.S. Food and Drug Administration.
The med is used to treat metastatic cutaneous squamous cell carcinoma, a rare skin cancer, in patients whose condition have not improved following surgery or chemotherapy.
Sanofi Genzyme and Regeneron will market the drug jointly in the U.S., selling at a list price of $9,100 for a three-week treatment cycle.
Read the Reuters report
[javascriptSnippet]